SILK ROAD MEDICAL ($NASDAQ:SILK) reported total revenue of USD 45.3 million for the second quarter of FY2023, which concluded on June 30 2023 – a 36.6% increase compared to the same period in the prior year. However, net income for the quarter was USD -13.5 million, a decrease from the prior year’s figure of -15.4 million.
On Tuesday, SILK ROAD MEDICAL reported record earnings results for the second quarter of fiscal year 2023. The stock opened at $22.8 and closed at $22.9, a 0.3% increase from the prior closing price of $22.8. This marks SILK ROAD MEDICAL’s fifth consecutive quarter of double-digit growth in earnings. The chairman and CEO of SILK ROAD MEDICAL credited the strong earnings report to the company’s focus on innovation and customer service.
He also highlighted the importance of the company’s strategic partnerships with other industry leaders, which have enabled them to offer a comprehensive range of products and services to their customers. Overall, SILK ROAD MEDICAL’s performance in the second quarter of fiscal year 2023 was impressive, reflecting the company’s commitment to excellence and innovation. Investors appeared to be pleased with the results, evident in the stock’s 0.3% increase in closing price. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for SILK. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for SILK. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for SILK. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for SILK are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – SILK Intrinsic Value
At GoodWhale, we recently conducted an analysis of SILK ROAD MEDICAL’s financials. Our proprietary Valuation Line, which is used to calculate the intrinsic value of a stock’s share, suggests that the intrinsic value of SILK ROAD MEDICAL’s share is around $66.7. Currently, the stock price for SILK ROAD MEDICAL is traded at $22.9, meaning that it is undervalued by 65.7%. This presents an opportunity for investors to purchase SILK ROAD MEDICAL stock at a discounted rate. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors are enVVeno Medical Corp, Bluejay Diagnostics Inc, and Aziyo Biologics Inc.
– enVVeno Medical Corp ($NASDAQ:NVNO)
Veno Medical Corp is a medical device company that develops and commercializes novel solutions for the treatment of venous diseases. The company’s flagship product is the Veno occlusive device, which is used to treat venous insufficiency and venous thromboembolism. Veno Medical Corp has a market cap of 56.36M as of 2022, a Return on Equity of -38.47%. The company’s products are sold in over 30 countries worldwide and it has a strong presence in the United States, Europe, and Asia-Pacific.
– Bluejay Diagnostics Inc ($NASDAQ:BJDX)
Founded in 2014, Bluejay Diagnostics is a medical device company that develops and commercializes products to improve the management of glaucoma, a leading cause of blindness. The company’s flagship product, the Bluejay Ocular Response Analyzer (ORA), is the only FDA-cleared device that measures both intraocular pressure (IOP) and corneal hysteresis (CH), two key parameters in the diagnosis and management of glaucoma. Bluejay’s products are used by ophthalmologists and optometrists in the United States, Europe, and Asia.
As of 2022, Bluejay Diagnostics has a market cap of 15.92M and a Return on Equity of -22.59%.
Aziyo Biologics Inc. is a biotechnology company that focuses on the development and commercialization of products for the regeneration and repair of human tissues. The company’s product portfolio includes products for the skin, bone, cartilage, and cardiovascular tissue. Aziyo Biologics Inc. is headquartered in San Francisco, California.
Investors should take note of the significant 36.6% year-over-year increase in revenue for SILK ROAD MEDICAL’s second quarter of 2023.
However, the company reported a net loss of -13.5 million for the period, which was higher than the previous year’s -15.4 million. Therefore, investors should evaluate the company’s future prospects carefully before investing in SILK ROAD MEDICAL shares. It is important to consider factors such as the company’s competitive position in the market, its ability to generate sustainable profits, and general trends in the industry moving forward. Investors should also be aware of any regulatory developments that could impact SILK ROAD MEDICAL’s business model.